TABLE 4.
Other polymorphisms of DILI-related genes identified in GWAS and CGS.
| Genes | Drug | Method | Cohort | OR | P | 95%Cl |
|---|---|---|---|---|---|---|
| PTPN22 rs2476601 | Amoxicillin-clavulanate | GWAS | 1,806 cases, 10,397 P (European) Cirulli et al. (2019) | 1.62 | 4 × 10−6 | 1.32–1.98 |
| 133 cases, 1,314 P (African-American) | 1.37 | 1.5 × 10−6 | 1.21–1.56 | |||
| 109 cases, 718 P (Hispanic Americans) Cirulli et al. (2019) | ||||||
| NRF2 rs4243387 | Anti-TB drugs | CGS | 314 cases, 628 P (Chinese) Chen et al. (2019) | 1.362 | 0.038 | 1.017–1.824 |
| MAFF rs2267373 | Anti-TB drugs | CGS | 314 cases, 628 P (Chinese) Chen et al. (2019) | 0.753 | 0.025 | 0.587–0.965 |
| NOS2A rs11080344 | Isoniazid | CGS | 18 cases, 82 T (Japanese) Nanashima et al. (2012) | 0.424 | 0.043 | 0.182–0.988 |
| Rifampicin | ||||||
| BACH1 rs2070401 | Isoniazid | CGS | 18 cases, 82 T (Japanese) Nanashima et al. (2012) | 016.2 | 0.018 | 1.577–166.387 |
| Rifampicin | ||||||
| MAFK rs4720833 | Isoniazid | CGS | 18 cases, 82 T (Japanese) Nanashima et al. (2012) | 3.162 | 0.037 | 1.033–9.686 |
| Rifampicin | ||||||
| XPO1 rs4430924 | Anti-TB drugs | CGS | 314 cases, 628 T (Chinese) He et al. (2019) | 1.938 | 0.039 | 1.035–3.628 |
| ERN1 rs199650082 | Efavirenz | GWAS | 21 cases, 234 T (African) Petros et al. (2017) | 18.2 | 1.4 × 10−6 | 7.1–46.9 |
| lincRNA rs4842407 | Efavirenz | GWAS | 42 cases, 292 T (African) Petros et al. (2017) | 5.4 | 5.3 × 10−7 | 2.8–10.3 |
OR, odds ratio; P, p value; 95%CI, 95% confidence interval; C, medication with adverse reactions; T, medication with no adverse reactions; PC, population control; U, unknown; Anti-TB drugs, Antituberculosis drugs.